A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladderEROGLU, Zeynep; FRUEHAUF, John P.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 1, pp 263-267, issn 0344-5704, 5 p.Article

Pharmacokinetics of single-agent axitinib across multiple solid tumor typesTORTORICI, Michael A; COHEN, Ezra E. W; PITHAVALA, Yazdi K et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1279-1289, issn 0344-5704, 11 p.Article

Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational ModelingFRIEBOES, Hermann B; EDGERTON, Mary E; FRUEHAUF, John P et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 10, pp 4484-4492, issn 0008-5472, 9 p.Article

A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent gliomaPARKER, Ricardo J; FRUEHAUF, John P; MEHTA, Rita et al.Journal of neuro-oncology. 2004, Vol 66, Num 3, pp 365-375, issn 0167-594X, 11 p.Article

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanomaEROGLU, Zeynep; KONG, Kevin M; JAKOWATZ, James G et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 4, pp 1081-1087, issn 0344-5704, 7 p.Article

The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. CommentaryMATHEWS, Marlon S; LINSKEY, Mark E; HASSO, Anton N et al.Surgical neurology. 2008, Vol 70, Num 6, pp 649-653, issn 0090-3019, 5 p.Article

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced MelanomaKIM, Kevin B; SOSMAN, Jeffrey A; PETERSON, Amy C et al.Journal of clinical oncology. 2012, Vol 30, Num 1, pp 34-41, issn 0732-183X, 8 p.Article

Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progressionEINSPAHR, Janine G; THOMAS, Tracy L; ALBERTS, David S et al.Cancer. 2007, Vol 110, Num 11, pp 2519-2527, issn 0008-543X, 9 p.Article

Breast cancer survival and in vitro tumor response in the extreme drug resistance assayMEHTA, Rita S; BORNSTEIN, Richard; YU, Ing-Ru et al.Breast cancer research and treatment. 2001, Vol 66, Num 3, pp 225-237, issn 0167-6806Article

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid TumorsRINI, Brian I; SCHILLER, Joan H; KIM, Sinil et al.Clinical cancer research (Print). 2011, Vol 17, Num 11, pp 3841-3849, issn 1078-0432, 9 p.Article

Breast cancer chemoprevention Phase I evaluation of biomarker modulation by Arzoxifene, a third generation selective estrogen receptor modulatorFABIAN, Carol J; KIMLER, Bruce F; GANZ, Patricia A et al.Clinical cancer research. 2004, Vol 10, Num 16, pp 5403-5417, issn 1078-0432, 15 p.Article

Factors associated with success of the extreme drug resistance assay in primary breast cancer specimensELLIS, Robert J; FABIAN, Carol J; MCGINNESS, Marilee et al.Breast cancer research and treatment. 2002, Vol 71, Num 2, pp 95-102, issn 0167-6806Article

Independent association of angiogenesis index with outcome in prostate cancerMEHTA, Rita; KYSHTOOBAYEVA, Ainura; KUROSAKI, Tom et al.Clinical cancer research. 2001, Vol 7, Num 1, pp 81-88, issn 1078-0432Article

Mathematical modeling of cancer progression and response to chemotherapySANGA, Sandeep; SINEK, John P; FRIEBOES, Hermann B et al.Expert review of anticancer therapy. 2006, Vol 6, Num 10, pp 1361-1376, issn 1473-7140, 16 p.Article

Endometriosis-associated ovarian carcinoma: Differential expression of vascular endothelial growth factor and estrogen/progesterone receptorsDEL CARMEN, Marcela G; SMITH SEHDEV, Anne E; NICKLES FADER, Amanda et al.Cancer. 2003, Vol 98, Num 8, pp 1658-1663, issn 0008-543X, 6 p.Article

Association between in vitro platinum Resistance in the EDR assay and clinical outcomes for ovarian cancer patientsHOLLOWAY, Robert W; MEHTA, Rita S; FINKLER, Neil J et al.Gynecologic oncology (Print). 2002, Vol 87, Num 1, pp 8-16, issn 0090-8258Article

Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimensHAROUN, Raymond I; CLATTERBUCK, Richard E; GIBBONS, M. Christopher et al.Journal of neuro-oncology. 2002, Vol 58, Num 2, pp 115-123, issn 0167-594XArticle

Development of an in vitro chemo-radiation response assay for cervical carcinomaMONK, Bradley J; BURGER, Robert A; PARKER, Ricardo et al.Gynecologic oncology (Print). 2002, Vol 87, Num 2, pp 193-199, issn 0090-8258, 7 p.Article

The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literatureREAVEY-CANTWELL, John F; HAROUN, Raymond I; ZAHURAK, Marianna et al.Journal of neuro-oncology. 2001, Vol 55, Num 3, pp 195-204, issn 0167-594XArticle